$CYCU News: Cycurion Announces Industry Veteran Kevin

New Post Public Reply Private Reply Replies (2) Message Board
Lee Adams Lee Adams #4656
194
$CYCU News: Cycurion Announces Industry Veteran Kevin O’Brien Joins Board of Directors

MCLEAN, Va., April 03, 2025 (GLOBE NEWSWIRE) -- Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces that industry veteran Kevin O’Brien has joined its Board of Directors, effective from the close of the Company’s recent de-SPAC transaction.

Kevin O’Brien brings more than 25 years of experience in the commercialization of Big Data, Artificial Intelligence, and Analytics, including three rounds as a top C-Suite executive and CEO. In his roles, he has designed, overseen, and implemented products that provide more timely, unbiased, and normalized actionable insights from public and anonymized sensors and data sets in sectors such as financial services, technology, business services, and national security. Kevin leverages his financial technology expertise and tradecraft to commercialize category-defining products and services focused on the unmet needs of information intensive enterprises, networks, and exchanges across the globe. He has also overseen each firm’s sales efforts, putting them on positive revenue growth trajectories, as well as having led multiple rounds of financings with strategic and financial investors for a total of more than $200 million. In addition, Mr. O’Brien has also been the force behind developing marketable AI models, indices, and tradable securities, consistently appearing in the media to explain his verifiable economic and security insights that give business and national security professionals real-time informational advantages.

“Cycurion has emerged as a leading cybersecurity provider,” commented Kevin O’Brien. “In particular, the recently announced groundbreaking AI-powered ARx Security Platform has the potential to revolutionize the cybersecurity market. I am delighted to have recently become a member of the Board of Directors, and I believe my decades of experience in the industry will help contribute to long-term growth and increasing Cycurion’s stockholder value.”

Mr. O’Brien is currently the President of Chainalysis Government Solutions (CGS), a wholly owned subsidiary of Chainalysis, Inc. and a leading provider of advanced blockchain analytics, software and solutions to financial services and government institutions across the globe. Prior to Chainalysis, Mr. O’Brien was the CEO of Orbital Insight, Inc., an industry defining geospatial software and analytics company that spearheaded the development and commercialization of advanced AI, Computer Vision, and Machine Learning technologies to deliver real time intelligence and insights to major commercial and government clients. Before joining Orbital Insight, he held executive positions at FactSet Research Systems, Inc., Revere Data, LLC, Gradience, Inc., and Reuters Group PLC.

Kevin originally trained as a software engineer working in the aerospace, electronics and systems integration industries. He holds a Bachelor of Business Administration degree in Management Information Systems from James Madison University, and an MBA in Innovation, Strategy and Information Technology from the EDHEC Business School in Nice, France. Mr. O’Brien holds dual nationality in the US and EU, has lived and worked in Germany, France, and the United Kingdom, and conducted business throughout Asia and the Middle East.

“Kevin’s deep experience in innovation, commercialization and corporate leadership make him a valued member of our Board,” said Kevin Kelly, Cycurion CEO. “Hise accomplishments as an executive in the IT cybersecurity field with extensive experience in both the private sector and governmental organizations and considerable expertise will be extremely valuable as we execute our growth strategies to capitalize on the rapidly growing global demand for cybersecurity solutions.”

About Cycurion
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients with a commitment to securing the digital future.

Forward looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.

Many factors could cause Cycurion’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-4, as filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in that filing with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Investor Contact:
CORE IR
investors@cycurion.com

Media Contact:
Phone: (703) 555-0123
Email: media@cycurion.com

https://www.globenewswire.com/newsroom/ti?nf=...IyOTg5MDA=
https://ml.globenewswire.com/media/NTRmMmU1Yz...curion.png Source: Cycurion
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytokinetics Faces Class Action: What You Need to Know

Updated Category News Views 175

Understanding the Class Action Lawsuit Against Cytokinetics Cytokinetics, Incorporated is currently facing a significant class action lawsuit initiated by shareholders. This legal challenge brings to light serious allegations against the Company regarding their disclosures and expectations for FDA approval of a key drug. Details of the Allegations The lawsuit asserts that...

Continue Reading
Discover the Embodied Luxury of the Champagne Specialist Course

Updated Category News Views 207

Verona Hosts the Esteemed Champagne Specialist Course The Italian Wine Academy is excited to announce a remarkable opportunity for wine enthusiasts and professionals. In Verona, for the very first time, the Academy will conduct the prestigious Comité Champagne 'Champagne Specialist' course. This unique program will be available in both English and Italian, providing an...

Continue Reading
MiniLuxe Achieves Strong Q1 2025 Growth with Strategic Focus

Updated Category News Views 378

MiniLuxe Reports Strong Financial Performance for Q1 2025 Reported figures all in U.S. Dollars MiniLuxe Holding Corp. (TSXV: MNLX) has announced exciting financial results for its first quarter of the year. This period showcased a significant 9% growth in revenue, reaching an impressive $6.1 million. Coupled with a gross profit of $2.5 million, reflective of a 12%...

Continue Reading
Transforming Shopify: AI Product Discovery for Enterprises

Updated Category News Views 141

Fredhopper's New App for Shopify Fredhopper Introduces Cutting-Edge Product Discovery Solutions The ecommerce landscape is evolving rapidly, and innovation is at the forefront. Fredhopper has launched its Product Discovery App for Shopify, bringing advanced AI-powered product search and personalized recommendations directly into the hands of enterprise merchants. This...

Continue Reading
Quantum Computing Inc. Faces Class Action Lawsuit for Shareholders

Updated Category News Views 162

Understanding the Recent Class Action Against Quantum Computing Inc. In a significant turn of events, Quantum Computing Inc. has come under legal pressure as a class action lawsuit has been filed on behalf of its shareholders. The lawsuit comes in response to allegations of misleading information that may have adversely affected investors' financial interests. Class...

Continue Reading